JANSSEN
Teclistamab in multiple myeloma
Janssen Pharmaceuticals announced the Phase 1b TriMM-2 study results in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy. Teclistamab is administered in combination with Darzalex Faspro (daratumumab and hyaluronidase).
The objective response rate was observed in 73.7% of patients with prior anti-CD38 exposure, and 66.7% of patients who achieved response were alive.
Imbruvica in chronic lymphocytic leukemia
The Janssen Pharmaceuticals announced the Phase 2 CAPTIVATE study, demonstrating the efficacy of Imbruvica (ibrutinib) plus venetoclax (I+V) in patients with untreated chronic lymphocytic leukemia. The combination has shown clinically meaningful progression-free survival (PFS) and overall survival (OS).
The Phase 2 CAPTIVATE enrolled 323 patients - after a median follow-up of 387 months, 88% of treated patients had a PFS rate of 36 months. The OS rate at 36-month was 98%. Across all the patient populations, the complete response was 57%.
NOVARTIS
Kymriah in B-cell ALL
Kymriah demonstrated durable remission and long-term survival in children and young adults suffering from B-cell acute lymphoblastic leukemia (ALL).
In the final ELIANA analysis, 55% of patients were alive after five years. 44% of patients who achieved remission within three months still had remission at the five-year mark.
ABBVIE
Epcoritamab IN LBCL
AbbVie presented the preliminary results of the Phase 2 trial of epcoritamab in patients with large B-cell lymphoma (LBCL). It announced that epcoritamab showed a durable response in patients who have previously received at least two anti-lymphoma therapies, including chimeric antigen receptor (CAR) T-cell therapy.
The trial included 157 relapsed/refractory LBCL patients; epcoritamab showed a complete response in39% of patients and an overall response rate in 63% of patients. 69% of patients who were naive to CAR T therapy achieved ORR, and 42% of patients achieved CR. The median duration of response was estimated to be 12 months, following a median follow-up of 10.7 months.